EGYPTIAN INTERNATIONAL PHARMACEUTICALS (EIPICO)
PHAR
Financial ResultsPositive News
EIPICO Rockets to EGP 603M Q1 Profit Amid Surging Sales
EIPICO reports a 217% surge in Q1-24 net profit to EGP 603M, driven by robust sales growth and strong standalone performance.
May 30, 2024 at 1:50:00 PMScore: 92

EIPICO, Egypt’s pharmaceutical powerhouse, delivered explosive growth in Q1-24. Consolidated net profit skyrocketed to EGP 603.62 million, a staggering 217% leap from EGP 188.41 million in Q1-23. Net sales surged 51% year-on-year to EGP 1.50 billion, reflecting robust demand. Standalone performance mirrored this success: net profit jumped 243% to EGP 626.14 million, with revenues hitting EGP 1.44 billion. Earnings per share (EPS) tripled to EGP 5.15, signaling strong investor returns. The company also reported a 28% annual profit increase in 2023, cementing its growth trajectory.
Recommended Actions
- Monitor EIPICO stock for potential breakout above 52-week high
- Consider accumulating shares on market dips
- Track pharmaceutical sector trends for broader industry insights
- Review EPS trajectory for dividend growth potential
- Set price alerts for EIPICO’s stock near EGP 49.50 resistance
Positive Aspects
- 217% consolidated profit growth
- 51% YoY sales surge
- Triple-digit standalone profit increase
- EPS growth of 180%
- Sustained annual profit momentum